Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zolmitriptan - AstraZeneca/Burroughs Wellcome

Drug Profile

Zolmitriptan - AstraZeneca/Burroughs Wellcome

Alternative Names: 311-C90; 311C; AscoTop; BW-311C90; Zomig; Zomig-ZMT; Zomigon

Latest Information Update: 10 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Burroughs Wellcome
  • Developer Amneal Pharmaceuticals; AstraZeneca
  • Class Analgesics; Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cluster headache; Menstrual migraine; Migraine

Most Recent Events

  • 05 Dec 2018 Zolmitriptan licensed to Grunenthal for worldwide commercialisation excluding Japan for the treatment of acute migraines and cluster headaches before December 2018
  • 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
  • 01 Nov 2017 Phase-III clinical trials in Migraine (In children) in USA (Intranasal) (NCT03275922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top